Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ECC 2015

25 Sep 2015

Messe Wien Exhibition & Congress Centre, Vienna, Austria

European Commission: Actions to tackle cancer

Dr Vytenis Andriukaitis - EU Commissioner for Health and Food Safety

European Commission: Actions to tackle cancer ( Dr Vytenis Andriukaitis - EU Commissioner for Health and Food Safety )

How do disparities affect cancer patients across Europe?

Prof Mark Lawler - Chair of the EAPM Research Subgroup

How do disparities affect cancer patients across Europe? ( Prof Mark Lawler - Chair of the EAPM Research Subgroup )

The importance of significant genetic variations between breast cancers

Dr Lucy Yates - Wellcome Trust Sanger Institute and the University of Cambridge, Cambridge, UK

The importance of significant genetic variations between breast cancers ( Dr Lucy Yates - Wellcome Trust Sanger Institute and the University of Cambridge, Cambridge, UK )

What is the AMORIS study?

Prof Mieke van Hemelrijck - Kings College London, London, UK

What is the AMORIS study? ( Prof Mieke van Hemelrijck - Kings College London, London, UK )

What is the European cancer accreditation programme?

Anke Wind, M.P.H - Netherlands Cancer Institute, Amsterdam, Netherlands

What is the European cancer accreditation programme? ( Anke Wind, M.P.H - Netherlands Cancer Institute, Amsterdam, Netherlands )

What are the obstacles in cancer prevention?

Prof Jack Cuzick - Queen Mary University of London, London, UK

What are the obstacles in cancer prevention? ( Prof Jack Cuzick - Queen Mary University of London, London, UK )

Epigenetics in cancer genesis

Dr Manel Esteller – Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain

Epigenetics in cancer genesis ( Dr Manel Esteller – Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain )

Results of 5 year phase III randomised trial treating localised prostate cancer

Prof David Dearnaley - Institute of Cancer Research, London, UK

Results of 5 year phase III randomised trial treating localised prostate cancer ( Prof David Dearnaley - Institute of Cancer Research, London, UK )

How has surgery developed over the last decade?

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy

How has surgery developed over the last decade? ( Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy )

Is lung cancer screening ready for implementation in Europe?

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy

Is lung cancer screening ready for implementation in Europe? ( Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy )

ECC 2015: Editor's highlights

Prof Gordon McVie - ecancer Managing Editor

ECC 2015: Editor's highlights ( Prof Gordon McVie - ecancer Managing Editor )

Surgery in synchronous oligometastatic disease

Prof Peter Naredi - University of Gothenburg, Gothenburg, Sweden

Surgery in synchronous oligometastatic disease ( Prof Peter Naredi - University of Gothenburg, Gothenburg, Sweden )

Are we providing adequate surgical care?

Prof Riccardo Audisio - President of the European Society for Surgical Oncology

Are we providing adequate surgical care? ( Prof Riccardo Audisio - President of the European Society for Surgical Oncology )

European Pharma companies to disclose health professional payments

Andrew Powrie-Smith - European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium

European Pharma companies to disclose health professional payments ( Andrew Powrie-Smith - European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium )

Diagnosis while pregnant should not lead to treatment delay or pregnancy termination

Prof Frederic Amant - Katholieke Universiteit Leuven, Leuven, Belgium

Diagnosis while pregnant should not lead to treatment delay or pregnancy termination ( Prof Frederic Amant - Katholieke Universiteit Leuven, Leuven, Belgium )

First ‘targeted’ treatment for small cell lung cancer shows promise

Dr Catherine Pietanza - Memorial Sloan Cancer Center, New York, USA

First ‘targeted’ treatment for small cell lung cancer shows promise ( Dr Catherine Pietanza - Memorial Sloan Cancer Center, New York, USA )

DDFMISO trial confirms significant negative prognostic value of tumour hypoxia

Prof Michael Baumann - University Hospital Carl Gustav Carus, Dresden, Germany

DDFMISO trial confirms significant negative prognostic value of tumour hypoxia ( Prof Michael Baumann - University Hospital Carl Gustav Carus, Dresden, Germany )

Results of a placebo controlled study of tasquinimod in men with metastatic castrate resistant prostate cancer

Dr Michael A. Carducci - Johns Hopkins University, Baltimore, USA

Results of a placebo controlled study of tasquinimod in men with metastatic castrate resistant prostate cancer ( Dr Michael A. Carducci - Johns Hopkins University, Baltimore, USA )

Brain metastases genomic analysis could reveal new targets for treatment

Prof Priscilla Brastianos - Massachusetts General Hospital, Boston, USA

Brain metastases genomic analysis could reveal new targets for treatment ( Prof Priscilla Brastianos - Massachusetts General Hospital, Boston, USA )

'Survivor passport' for survivors of childhood leukaemia

Prof Martin Schrappe - University Medical Center Schleswig-Holstein, Kiel, Germany

'Survivor passport' for survivors of childhood leukaemia ( Prof Martin Schrappe - University Medical Center Schleswig-Holstein, Kiel, Germany )

Hodgkin lymphoma incidence in young affected by social deprivation, gender

Dr Richard McNally - Newcastle University, Newcastle, UK

Hodgkin lymphoma incidence in young affected by social deprivation, gender ( Dr Richard McNally - Newcastle University, Newcastle, UK )

Progression of childhood cancers in Europe

Prof Gilles Vassal - University Paris-Sud, Orsay, France

Progression of childhood cancers in Europe ( Prof Gilles Vassal - University Paris-Sud, Orsay, France )

HPV vaccines for cancer prevention

Prof Jack Cuzick - Queen Mary University of London, London, UK

HPV vaccines for cancer prevention ( Prof Jack Cuzick - Queen Mary University of London, London, UK )

Is it possible to develop cancer drugs at a lower cost?

Prof Andrew Hill - University of Liverpool, Liverpool, UK

Is it possible to develop cancer drugs at a lower cost? ( Prof Andrew Hill - University of Liverpool, Liverpool, UK )

Examining NSCLC responses to durvalumab monotherapy

Brandon Higgs - MedImmune, Gaithersburg, USA

Examining NSCLC responses to durvalumab monotherapy ( Brandon Higgs - MedImmune, Gaithersburg, USA )

Expanding access to crizotinib using a biomarker-driven approach

Prof Gilles Vassal - University Paris-Sud, Orsay, France

Expanding access to crizotinib using a biomarker-driven approach ( Prof Gilles Vassal - University Paris-Sud, Orsay, France )

ECC 2015 scientific highlights

Prof Peter Naredi - University of Gothenburg, Gothenburg, Sweden

ECC 2015 scientific highlights ( Prof Peter Naredi - University of Gothenburg, Gothenburg, Sweden )

Time between melanoma excision and sentinel node biopsy does not affect survival

Charlotte Oude Ophuis - Erasmus MC Cancer Institute, Rotterdam, Netherlands

Time between melanoma excision and sentinel node biopsy does not affect survival ( Charlotte Oude Ophuis - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Atezolizumab limits disease progression for metastatic urothelial bladder cancer

Dr Jonathan E. Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

Atezolizumab limits disease progression for metastatic urothelial bladder cancer ( Dr Jonathan E. Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

Atezolizumab for locally advanced or metastatic PD-L1-selected NSCLC

Dr Benjamin Besse - Institut Gustave Roussy, Villejuif, France

Atezolizumab for locally advanced or metastatic PD-L1-selected NSCLC ( Dr Benjamin Besse - Institut Gustave Roussy, Villejuif, France )

Rova-T: First ‘targeted’ treatment for small cell lung cancer shows promise

Dr Catherine Pietanza - Memorial Sloan Kettering Cancer Center, New York, USA

Rova-T: First ‘targeted’ treatment for small cell lung cancer shows promise ( Dr Catherine Pietanza - Memorial Sloan Kettering Cancer Center, New York, USA )

A cancer diagnosis while pregnant should not lead to treatment delay or pregnancy termination

Prof Frédéric Amant - Katholieke Universiteit Leuven, Leuven, Belgium

A cancer diagnosis while pregnant should not lead to treatment delay or pregnancy termination ( Prof Frédéric Amant - Katholieke Universiteit Leuven, Leuven, Belgium )

Social deprivation and gender affects incidence of Hodgkin lymphoma in children and young adults

Dr Richard McNally - Newcastle University, Newcastle, UK

Social deprivation and gender affects incidence of Hodgkin lymphoma in children and young adults ( Dr Richard McNally - Newcastle University, Newcastle, UK )

Multi-peptide vaccine for kidney cancer fails to improve survival

Dr Brian Rini - Cleveland Clinic Foundation, Cleveland, USA

Multi-peptide vaccine for kidney cancer fails to improve survival ( Dr Brian Rini - Cleveland Clinic Foundation, Cleveland, USA )

Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC

Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium

Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )

Latest in lung cancer from ECC 2015

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Latest in lung cancer from ECC 2015 ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

Survival in all gastrointestinal cancers improved by aspirin post diagnosis

Ms Martine Frouws - Leiden University Medical Center, Leiden, The Netherlands

Survival in all gastrointestinal cancers improved by aspirin post diagnosis ( Ms Martine Frouws - Leiden University Medical Center, Leiden, The Netherlands )

Watchful waiting versus neck dissection in patients with head and neck cancers

Prof Hisham Mehanna - University of Birmingham, Birmingham, UK

Watchful waiting versus neck dissection in patients with head and neck cancers ( Prof Hisham Mehanna - University of Birmingham, Birmingham, UK )

How can we improve current treatments for osteosarcomas?

Prof Stefan Bielack - Klinikum Stuttgart, Stuttgart, Germany

How can we improve current treatments for osteosarcomas? ( Prof Stefan Bielack - Klinikum Stuttgart, Stuttgart, Germany )

Over three-quarters of people with cancer worldwide have no access to safe surgery

Prof Richard Sullivan - King's College London, London, UK

Over three-quarters of people with cancer worldwide have no access to safe surgery ( Prof Richard Sullivan - King's College London, London, UK )

Majority of cancer patients worldwide have no access to safe surgery

Prof Richard Sullivan - King's College London, London, UK

Majority of cancer patients worldwide have no access to safe surgery ( Prof Richard Sullivan - King's College London, London, UK )

Add panitumumab or bevacizumab to improve first-line metastatic colorectal cancer therapy?

Dr Fernardo Rivera - Hospital Universitario Marques de Valdecilla, Santander, Spain

Add panitumumab or bevacizumab to improve first-line metastatic colorectal cancer therapy? ( Dr Fernardo Rivera - Hospital Universitario Marques de Valdecilla, Santander, Spain )

Regional lymph node irradiation in early breast cancer

Prof Philip Poortmans - Radboud University Medical Center, Nijmegen, The Netherlands

Regional lymph node irradiation in early breast cancer ( Prof Philip Poortmans - Radboud University Medical Center, Nijmegen, The Netherlands )

Hormonal suppression prevents ovarian failure, preserves fertility in women with breast cancer

Dr Matteo Lambertini - Ospedale San Martino, Genoa, Italy

Hormonal suppression prevents ovarian failure, preserves fertility in women with breast cancer ( Dr Matteo Lambertini - Ospedale San Martino, Genoa, Italy )

Post diagnosis aspirin improves survival in all gastrointestinal cancers

Ms Martine Frouws - Leiden University Medical Center, Leiden, Netherlands

Post diagnosis aspirin improves survival in all gastrointestinal cancers ( Ms Martine Frouws - Leiden University Medical Center, Leiden, Netherlands )

Preventing ovarian failure and preserve fertility in women with breast cancer with hormonal therapy

Dr Matteo Lambertini - Ospedale San Martino, Genoa, Italy

Preventing ovarian failure and preserve fertility in women with breast cancer with hormonal therapy ( Dr Matteo Lambertini - Ospedale San Martino, Genoa, Italy )

ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review

Dr Claire Vale - MRC Clinical Trials Unit at UCL, London, UK

ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review ( Dr Claire Vale - MRC Clinical Trials Unit at UCL, London, UK )

PD-L2 expression and its relevance to anti-PD-1 therapy in cancer

Dr Jennifer Yearley - Merck Research Labs, Biologics Discovery, Palo Alto, USA

PD-L2 expression and its relevance to anti-PD-1 therapy in cancer ( Dr Jennifer Yearley - Merck Research Labs, Biologics Discovery, Palo Alto, USA )

Dabrafenib plus trametinib improves melanoma patients’ survival

Prof Caroline Robert - Institute Gustave Roussy, Villejuif, France

Dabrafenib plus trametinib improves melanoma patients’ survival ( Prof Caroline Robert - Institute Gustave Roussy, Villejuif, France )

COMBI-V: Melanoma survival improved by targeted drug combination

Prof Caroline Robert - Institute Gustave Roussy, Villejuif, France

COMBI-V: Melanoma survival improved by targeted drug combination ( Prof Caroline Robert - Institute Gustave Roussy, Villejuif, France )

Economics of radiotherapy and radiotherapy boost for high grade invasive breast cancer

Prof Philip Poortmans - University Medical Center, Nijmegen, The Netherlands

Economics of radiotherapy and radiotherapy boost for high grade invasive breast cancer ( Prof Philip Poortmans - University Medical Center, Nijmegen, The Netherlands )

EORTC ‘boost no-boost’ trial 20-year follow up: Impact of pathological factors on long-term local control

Dr Conny Vrieling - Clinique des Grangettes, Geneva, Switzerland

EORTC ‘boost no-boost’ trial 20-year follow up: Impact of pathological factors on long-term local control ( Dr Conny Vrieling - Clinique des Grangettes, Geneva, Switzerland )

Cabozantinib improves advanced kidney cancer survival: METEOR trial results

Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib improves advanced kidney cancer survival: METEOR trial results ( Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Melanoma immunotherapy latest and TVEC plus pembrolizumab

Dr Georgina Long - University of Sydney, Sydney, Australia

Melanoma immunotherapy latest and TVEC plus pembrolizumab ( Dr Georgina Long - University of Sydney, Sydney, Australia )

Genetic screening of brain metastases could reveal new targets for treatment

Prof Priscilla Brastianos - Massachusetts General Hospital, Boston, USA

Genetic screening of brain metastases could reveal new targets for treatment ( Prof Priscilla Brastianos - Massachusetts General Hospital, Boston, USA )

NETTER-1: Targeted radionuclide therapy improves PFS in mid-gut NETs

Prof Philippe Ruszniewski - Paris Diderot University, Paris, France

NETTER-1: Targeted radionuclide therapy improves PFS in mid-gut NETs ( Prof Philippe Ruszniewski - Paris Diderot University, Paris, France )

RADIANT-4: Results of international trial show promise in the treatment of neuroendocrine tumours

Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA

RADIANT-4: Results of international trial show promise in the treatment of neuroendocrine tumours ( Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA )

Mid-gut NETs respond to targeted radionuclide therapy: NETTER-1 results

Prof Philippe Ruszniewski - Paris Diderot University, Paris, France

Mid-gut NETs respond to targeted radionuclide therapy: NETTER-1 results ( Prof Philippe Ruszniewski - Paris Diderot University, Paris, France )

Comment: EUROCARE-5, large blood cancer survival differences throughout Europe

Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium

Comment: EUROCARE-5, large blood cancer survival differences throughout Europe ( Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium )

Comment: New immunotherapy options for kidney cancer

Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium

Comment: New immunotherapy options for kidney cancer ( Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium )

Tackling global radiotherapy shortfall could save millions of lives and boost the economy of poorer countries

Prof Rifat Atun - Harvard University, Boston, USA

Tackling global radiotherapy shortfall could save millions of lives and boost the economy of poorer countries ( Prof Rifat Atun - Harvard University, Boston, USA )

Large variations found in survival from blood cancers between European countries

Dr Milena Sant - Istituto Nazionale Tumori, Milan, Italy

Large variations found in survival from blood cancers between European countries ( Dr Milena Sant - Istituto Nazionale Tumori, Milan, Italy )

CheckMate 025 trial results: Nivolumab versus everolimus in pre-treated advanced kidney cancer

Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA

CheckMate 025 trial results: Nivolumab versus everolimus in pre-treated advanced kidney cancer ( Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA )

Everolimus for non-functional neuroendocrine tumours

Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA

Everolimus for non-functional neuroendocrine tumours ( Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA )

EUROCARE-5 results show large variations in survival from blood cancers between European countries

Dr Milena Sant - Istituto Nazionale Tumori, Milan, Italy

EUROCARE-5 results show large variations in survival from blood cancers between European countries ( Dr Milena Sant - Istituto Nazionale Tumori, Milan, Italy )

Nivolumab improves overall survival for advanced kidney cancer

Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA

Nivolumab improves overall survival for advanced kidney cancer ( Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA )

METEOR trial results: Cabozantinib improves advanced kidney cancer survival

Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

METEOR trial results: Cabozantinib improves advanced kidney cancer survival ( Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer